| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen |
2009-012981-30: Prospective study to assess the efficacy and safety of lanreotide 120 mg as treatment of clinical symptoms associated with inoperable intestinal obstruction |
|
|
| Ongoing | 2 | 40 | Europe | Lanreotide, Solution for injection, Somatuline Autogel Injectable | University Hospital Ghent | Inoperable malignant bowel obstruction | | | | |
2011-003687-78: Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) LANREOTIDE AUTOGEL NELTRATTAMENTO DEI PAZIENTI CON FIBROSI POLMONARE IDIOPATICA |
|
|
| Ongoing | 2 | 10 | Europe | Gallium68-Dota-Noc, NA, Solution for injection | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI, IPSEN | Idiopathic Pulmonary Fibrosis Fibrosi polmonare interstiziale idiopatica, Idiopathic Pulmonary Fibrosis Fibrosi polmonare interstiziale idiopatica, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2013-004232-29: The effect of lanreotide on therapy resistant gastro-esophageal reflux |
|
|
| Ongoing | 2 | 15 | Europe | lanreotide autogel 120 mg, H01CB03, Gel for injection, Somatuline Autogel Injectable 120 mg | UZ Brussel, IPSEN NV | patients with persistent endoscopic reflux in spite of maximal medical therapy with PPI 2 x 40 mg pantoprazole before breakfast and dinner and 300 mg of H2 blocker ranitidine at bedtime AND continuing pathological reflux proven on impedancemetry., Persistent therapy resistant gastric esophageal reflux, Diseases [C] - Digestive System Diseases [C06] | | | | |
2005-004300-36: Use of somatostatin analogue therapy as primary medical treatment of acromegaly |
|
|
| Ongoing | 2 | 10 | Europe | Somatuline Autogel, Somatuline Autogel 60mg, Somatuline Autogel 90mg, Somatuline Autogel 120mg, Somatuline Autogel 60mg, Somatuline Autogel 90mg, Somatuline Autogel 120mg | Plymouth Hospital NHS Trust, R&D dept | Acromegaly | | | | |
2009-016082-29: Role of Lanreotide in the Management of Paraduodenal Pancreatitis |
|
|
| Ongoing | 2 | 60 | Europe | Somatuline Autogel 90 mg, Somatuline Autogel 90 mg | Erasme hospital | Paraduodenal pancreatitis | | | | |
| Ongoing | 2 | 20 | Europe | Metformina TEVA, IPSTYL, [Metformina], [IPSTYL], Tablet, Powder and solvent for solution for injection, METFORMINA TEVA - 30 CPR RIVESTITE IN BLISTER BIANCO OPACO PVC/PVDC/AL DA 850 MG, IPSTYL - 30 MG/2 ML POLVERE E SOLVENTE PER SOSPENSIONE INIETTABILE A RILASCIO PROLUNGATO PER USO INTRAMUSCOLARE1 FLACONE POLVERE + 1 FIALA SOLVENTE 2 ML | FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", IPSEN S.P.A. | Patients with progressive advanced Well-differentiated gastro-intestinal (GI) or lung carcinoids. Tumore neuroendocrino gastro-intestinale (GI) o carcinoide polmonare ben differenziato in stadio avanzato e/o non resecabile, Advanced neuroendocrine tumor Tumore neuroendocrino in stadio avanzato, Diseases [C] - Hormonal diseases [C19] | | | | |
| Active, not recruiting | 2 | 10 | US | Lanreotide, Somatuline Depot | Antonio Fojo, Ipsen | Paraganglioma, Pheochromocytoma | 03/26 | 03/26 | | |
NCT05048901: Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors |
|
|
| Recruiting | 1/2 | 49 | RoW | Cabozantinib, Cabometyx, Lanreotide, Somatuline | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Tri-Service General Hospital, Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital | Neuroendocrine Tumors,Gastroenteropancreatic | 08/26 | 12/26 | | |
